Business Monitor International


Zimbabwe Pharmaceuticals & Healthcare Report

Published 04 March 2014

  • 86 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Zimbabwe Pharmaceuticals & Healthcare Report

BMI View: Zimbabwe's pharmaceutical and healthcare sector continues to be affected by the scarcity of medical professionals, along with acute shortages of critical medicines and medical supplies. The lack of access to medical treatment has led to a large proportion of the population becoming more reliant on herbal and traditional medicine, which has seen a recent influx in the country. However, with the Zimbabwean authorities pushing for the regulation of herbal medicines, the current lack of competition within the pharmaceutical sector could provide opportunities for foreign drugmakers that are prepared to accept high risks.

Headline Expenditure Projections

  • Pharmaceuticals: US$233mn in 2013 to US$256mn in 2014; +9.7% in US dollar terms. Forecast remains in line with last quarter's projections.

Risk/Reward Rating

In BMI's RRR table for Q2 2014, Zimbabwe scored 29 out of 100, a slight improvement from last quarter (28). The country has also moved up one position from 29th to 28th in the 30 markets surveyed in the Middle East and Africa (MEA) region. This is attributed to an improvement in its industry reward score. Zimbabwe will, however, remain one of the least-attractive pharmaceutical and healthcare markets regionally and globally, due to the elevated political, economic and social risks, as well as the lack of finances for adequate healthcare provision and capacity utilisation.

Key Trends And Developments

February

The Medicines Control Authority of Zimbabwe (MCAZ) has called for the regulation of herbal medicine sector, which for a long time has operated without much regulation. New regulations for the sector have been submitted to the Ministry of Health and Child Care for approval. This comes in the wake of an influx of herbal medicines in the country, with some traders claiming that they treat more than 100 illnesses, including diabetes and liver dysfunction. The regulation of the herbal medicines sector was designed to ensure public safety with the...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
14
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Zimbabwe Pharmaceutical Sales, Historical Data and Forecasts, 2010-2018
16
Healthcare Market Forecast
16
Prescription Drug Market Forecast
17
Patented Drug Market Forecast
17
Generic Drug Market Forecast
18
Pharmaceutical Trade Forecast
19
Table: Zimbabwe Pharmaceutical Trade Data And Forecasts (US$mn), 2010-2018
20
Table: Zimbabwe Pharmaceutical Trade Data And Forecasts (ZWDmn)
21
Other Healthcare Data
21
Key Risks To BMI's Forecast Scenario
22
Macroeconomic Forecasts
24
Industry Forecast
24
Table: Zimbabwe - Economic Activity
28
Industry Risk Reward Ratings
29
Middle East And Africa Risk/Reward Ratings
29
Zimbabwe Risk/Reward Ratings
37
Rewards
37
Risks
37
Market Overview
39
Industry Trends And Developments
40
Epidemiology
40
Healthcare Sector
44
Table: Zimbabwe: Healthcare Facilities
45
Healthcare Funding
46
Health Insurance
48
Healthcare Staff
49
Traditional Medicine
50
Biotechnology
50
Clinical Trials
51
Regulatory Development
53
Regulatory Regime
53
Intellectual Property Developments
55
Counterfeit Drugs
56
Pricing And Reimbursement Regimes
56
Public Drug Procurement
57
Competitive Landscape
59
Pharmaceutical Industry
59
Domestic Industry
60
Foreign Industry
61
Pharmaceutical Sector Developments
61
Retail Pharmacy Sector
63
Company Profile
64
Datlabs
64
Varichem Laboratories
66
Ranbaxy
70
Pfizer
72
Demographic Forecast
75
Table: Zimbabwe's Population By Age Group, 1990-2020 ('000)
76
Table: Zimbabwe's Population By Age Group, 1990-2020 (% of total)
77
Table: Zimbabwe's Key Population Ratios, 1990-2020
78
Table: Zimbabwe's Rural And Urban Population, 1990-2020
78
Glossary
79
Methodology
81
Pharmaceutical Expenditure Forecast Model
81
Healthcare Expenditure Forecast Model
81
Notes On Methodology
82
Risk/Reward Ratings Methodology
83
Ratings Overview
84
Table: Pharmaceutical Risk/Reward Ratings Indicators
84
Indicator Weightings
85

The Zimbabwe Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Zimbabwe Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Zimbabwean pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Zimbabwe to test other views - a key input for successful budgeting and strategic business planning in the Zimbabwean pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Zimbabwean pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Zimbabwe.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc